Clinical Daily Summary
Clinical Daily Summary: What Happened on October 31, 2026
Life Biosciences reports early ER-100 update in three glaucoma patients
The company reported possible vision improvement and no major safety concerns so far at the low dose.
Today in brief
Three glaucoma patients received low-dose ER-100, and Life Biosciences reported possible signs of improved vision and no major safety concerns so far.1
Early ER-100 update
ER-100 uses OSK factors in an attempt to address vision conditions.1 The roundup’s author says the results are too early to support strong conclusions and raises concerns about possible risks from OSK.1